A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

But it should be. Here's what you need to know about RSV and the vaccines. RSV is a common respiratory virus that typically causes mild, cold-like symptoms, such as a runny nose, coughing ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Older adults in England are being urged by health officials to get vaccinated against respiratory syncytial virus (RSV). More than one million people aged 75 to 79, or those turning 80 after ...

More Alberta seniors are now eligible for a provincially funded RSV vaccine. The provincial government announced in October it would provide the RSV shot, Abrysvo, for free to seniors 60 and up ...

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...

A recent study found that the respiratory syncytial virus vaccine was highly effective in older U.S. veterans during the 2023-2024 respiratory illness season. The study, published Jan. 20 in The ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...

The federal government is investing $174.5m to provide eligible pregnant women with the RSV vaccine, Abrysvo, under the National Immunisation Program from Monday. This new vaccine will help ...